How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

EN

NASDAQ:ENLV
Get a brief AI stock analysisSaves ~ 15 minutes of your time

EN

Enlivex Therapeutics LtdNASDAQ ENLV Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is ENLV undervalued compared to its fair value?

The fair value of ENLV stock is hidden USD. Relative to the market price of 1.355 USD Enlivex Therapeutics Ltd is hidden.

Enlivex Therapeutics Ltd. is a clinical stage macrophage reprogramming immunotherapy company, which develops Allocetra,a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state...[More about valuation]

Enlivex Therapeutics Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

0.029 $B

Price:

1.355 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.321

FINANCIALS

Enlivex Therapeutics financial for reporting period

Income Statement


Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0056 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.006 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

Balance Sheet

0.047 B
0.039 B

Financial Position Analysis

Assets

0.047 B
Current Assets
0.032 B
Total non-current assets
0.015 B

Total current liabilities
0.0043 B
Total non-current liabilities
0.0038 B

Cash Flow Statement

-0.0055 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0054 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Enlivex Therapeutics fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is ENLV attractive for investment based on fundamental analysis?

ENLV stock rating is hidden. Enlivex Therapeutics is a hidden by Eyestock methodology.

Get ENLV Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

Debt / Equity ratio:

ROE:

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

ENLV analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for ENLV to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Enlivex Therapeutics Ltd competitors

AB

ABBV

Abbvie Inc

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Ill...

Discover

AM

AMGN

Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company...

Discover

VR

VRTX

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs fo...

Discover

Enlivex Therapeutics Ltd dividends

ENLV dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About ENLV stock

About the company Enlivex Therapeutics Ltd

Market cap $B

0.029

Dividend yield

Shares outstanding

18.4032 B

Enlivex Therapeutics Ltd. is a clinical stage macrophage reprogramming immunotherapy company, which develops Allocetra,a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

ENLV profile

  • Ticker

    ENLV

  • Country

    Israel

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    30 July 2014

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    71

  • City

    Ness Ziona

  • Address

    14 Einstein St.

  • Cusip

    M4130Y106